H. McKnight

Phosphatase inhibition augments anti-CD22-mediated signaling and cytotoxicity in non-hodgkin's lymphoma cells.

R. O’Donnell, D. Pearson, H. McKnight, 2009, Leukemia research.

Anti-CD 22 Monoclonal Antibody Enhances Bortezomib-mediated Lymphomacidal Activity in a Sequence Dependent Manner Permalink

Donnell, H. McKnight, J. Tuscano, 2012 .

The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner

R. O’Donnell, H. McKnight, J. Tuscano, 2011, Journal of hematology & oncology.

Imaging and Pharmacokinetics of 64Cu-DOTA-HB22.7 Administered by Intravenous, Intraperitoneal, or Subcutaneous Injection to Mice Bearing Non-Hodgkin’s Lymphoma Xenografts

C. Abbey, J. Sutcliffe, D. Kukis, 2009, Molecular Imaging and Biology.

Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts

R. O’Donnell, D. Pearson, H. McKnight, 2009, Cancer Immunology, Immunotherapy.

Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma.

H. McKnight, J. Tuscano, T. Wun, 2004, Leukemia research.

Phosphorylation abnormalities: NZB mice exhibit a B-cell signalling defect.

M. Gershwin, H. McKnight, J. Tuscano, 2002, Journal of autoimmunity.

CD22-Binding Peptides Derived from Anti-CD22 Ligand Blocking Antibodies Retain the Targeting and Cell Killing Properties of the Parent Antibodies and May Serve as a Drug Delivery Vehicle

K. Lam, D. Pearson, H. McKnight, 2008, International Journal of Peptide Research and Therapeutics.

Treatment of non-Hodgkin’s lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy

D. Pearson, H. McKnight, Y. Ma, 2009, Cancer Immunology, Immunotherapy.